Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Next Previous
Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Claseprubart (Primary) ; Claseprubart (Primary)
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy
  • Focus Registrational; Therapeutic Use
  • Acronyms CAPTIVATE
  • Sponsors Dianthus Therapeutics

Most Recent Events

  • 09 Mar 2026 According to a Dianthus Therapeutics media release, company announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for March 9, 2026 at 8:00 a.m. ET.
  • 09 Mar 2026 According to a Dianthus Therapeutics media release, company announced Early GO decision has been reached in the Part A of the trial ahead of Q2 2026 guidance. And , the company expects to provide CAPTIVATE Part B top-line guidance by end of 2026.
  • 11 Mar 2025 According to a Dianthus Therapeutics media release, interim responder analysis anticipated in second half of 2026 (2H26).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top